3′-or 2′-hydroxymethyl substituted nucleoside...

Details 3′-or 2′-hydroxymethyl substituted nucleoside... 3′-or 2′-hydroxymethyl substituted nucleoside...

2006-08-22

2006-08-22

Wilson, James O. (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S050000, C514S051000, C514S052000

Reexamination Certificate

active

07094770

ABSTRACT:
The present invention relates to a composition for and a method of treating hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, hepatitis D virus (HDV) infection or a proliferative disorder in a patient using an effective amount of a compound selected from the group consisting of formulas [I]–[IV] below and mixtures of two or more thereof:wherein the substituents are as defined herein. Pharmaceutical compositions comprising these compounds in combination with other HBV, HCV, or HDV agents is also disclosed.

REFERENCES:
patent: 3480613 (1969-11-01), Walton et al.
patent: 5534535 (1996-07-01), Townsend et al.
patent: 5905070 (1999-05-01), Schinazi et al.
patent: 5977061 (1999-11-01), Holy et al.
patent: 6004939 (1999-12-01), Chen et al.
patent: 6159951 (2000-12-01), Karpeisky et al.
patent: 6248878 (2001-06-01), Matulic-Adamic et al.
patent: 6271212 (2001-08-01), Chu et al.
patent: 6340690 (2002-01-01), Bachand et al.
patent: 6395716 (2002-05-01), Gosselin et al.
patent: 6444652 (2002-09-01), Gosselin et al.
patent: 6573248 (2003-06-01), Ramasamy et al.
patent: 2002/0055483 (2002-05-01), Watanabe et al.
patent: 2002/0147160 (2002-10-01), Bhat et al.
patent: 2003/0008841 (2003-01-01), Devos et al.
patent: 2003/0028013 (2003-02-01), Wang et al.
patent: 2003/0050229 (2003-03-01), Sommadossi et al.
patent: 2003/0083307 (2003-05-01), Devos et al.
patent: 2003/0087873 (2003-05-01), Stuyver et al.
patent: 1163103 (1969-09-01), None
patent: 1209654 (1970-10-01), None
patent: 06211890 (1994-02-01), None
patent: WO 93/12131 (1993-06-01), None
patent: WO 98/16184 (1998-04-01), None
patent: WO 99/43691 (1999-09-01), None
patent: WO 00/09531 (2000-02-01), None
patent: WO 01/10882 (2001-02-01), None
patent: WO 01/16671 (2001-03-01), None
patent: WO 01/32153 (2001-05-01), None
patent: WO 01/60315 (2001-08-01), None
patent: WO 01/68663 (2001-09-01), None
patent: WO 01/79246 (2001-10-01), None
patent: WO 01/90121 (2001-11-01), None
patent: WO 01/91737 (2001-12-01), None
patent: WO 01/96353 (2001-12-01), None
patent: WO 02/03997 (2002-01-01), None
patent: WO 02/18404 (2002-03-01), None
patent: WO 02/32920 (2002-04-01), None
patent: WO 02/48165 (2002-06-01), None
patent: WO 02/057287 (2002-07-01), None
patent: WO 02/057425 (2002-07-01), None
patent: WO 02/070533 (2002-09-01), None
patent: WO 02/094289 (2002-11-01), None
patent: WO 02/100415 (2002-12-01), None
patent: WO 03/026589 (2003-04-01), None
patent: WO 03/026675 (2003-04-01), None
patent: WO 03/051899 (2003-06-01), None
patent: WO 03/061385 (2003-07-01), None
patent: WO 03/061576 (2003-07-01), None
patent: WO 03/062255 (2003-07-01), None
patent: WO 03/062256 (2003-07-01), None
patent: WO 03/062257 (2003-07-01), None
patent: WO 03/063771 (2003-08-01), None
patent: WO 03/068162 (2003-08-01), None
patent: WO 03/072757 (2003-09-01), None
patent: WO 03/093290 (2003-11-01), None
McGuigan et al., “Alkyl hydrogen phosphonate derivatives of the anti-HIV agent AZT may be less toxic than the parent nucleoside analogue”, Antiviral Chemistry and Chemotherapy, 1994, 5(4), 271-277.
Fedorov, I., et al., XIII International Round Table: Nucleosides, Nucleotides and Their Biological Applications. Montpellier, France, Sep. 6-10, 1998. Poster 35.
Kato, K., et al., XIII International Round Table: Nucleosides, Nucleotides and Their Biological Applications. Montpellier, France, Sep. 6-10, 1998. Poster 49.
Svansson, L., et al., J. Org. Chem., 1991, 56: 2993-97.
Wengel, J., et al., Bioorganic & Medicinal Chemistry, vol. 3, No. 9, pp. 1223-1229, 1995.
Lin, T., et al., J. Med. Chem., 1993, 36:353-62.
Gauvry, N., et al., Tetrahedron 55 (1999) 1321-28.
Sterzyncki, R., et al., Nucleosides & Nucleotides, 10(1-3), 291-94 (1991).
Lee-Ruff, E., et al., J. Med. Chem., 1996, 39:5276-80.
Bamford, M., et al., J. Med. Chem., 1990, 33:2494-2501.
Tino, J., J. Med. Chem, 1993, 36:1221-29.
Brown, B., J. Org. Chem., 1998, 63:8012-18.
Pudlo, J., Nucleosides & Nucleotides, 11(2-4), 279-93 (1992).
Fiandor, J., et al., Nucleosides & Nucleotides, 8(5&6), 1107-8 (1989).
Jeong, L., et al., Nucleosides & Nucleotides, 16(7-9), 1059-62 (1997).
Jorgensen, P., et al., Nucleosides & Nucleotides, 16(7-9), 1063-66 (1997).
Frieden, M., et al., J. Chem. Soc. Perkin Trans I, 1998, 2827-32.
Slusarchyk, W., J. Med Chem., 1992, 35:1799-1806.
Bisacchi, G., et al., J. Med. Chem., 1991, 34:1415-21.
Qiu, Y., et al., J. Med. Chem., 1998, 41:10-23.
Sekiyama, T., J. Med. Chem., 1998, 41:1284-98.
Altmann, K.H., et al., “The Synthesis of 1′-methyl carbocyclic thymidine and its effect on nucleic acid duplex stability”,Synlett, Thieme Verlag, Stuttgart, De, Oct. 1994, 10, 853-855.
Baginsky, S.G. et al., “Mechanism of action of a pestivirus antiviral compound,”Proc. Nat. Acad. Sci. (USA) 2000, 97(14), 7981-7986.
Beigelman, L.N., et al, “Dimerization during the acetolysis of 3-O-acetyl-t-O-benzoyl-1,2-O-isopropylidene-3-C-methyl-α-D-ribofruanose. synethesis of 3′-C-methylnucleosides with the β-D-ribo-and α-D-arabinoconfigurations”,Carbohydrate Research, 1988, 181, 77-88.
Beigelman, L.N., et al, “A general method for synthesis of 3′-C-alkylnucleosides”,Nucleic Acids Symp. Ser., 1981, 9, 116-119.
Berenguer et al, “Hepatitis B and C Viruses: Molecular Identification and Targeted Antiviral Therapies,”Proceedings of the Association of American Physicians, 1998, 110(2), 98-112.
Carroll, S.S., et al. “Inhibition of Hepatitis C Virus RNA Replication by 2′-Modified Nucleoside Analogs,”The Journal of Biological Chemistry, 2003, 278(14), 11979-11984.
Czernecki, S., et al, “Syntheses if Various 3′-Brached 2′,3′-Unsaturated Pyrimidine Nucleosides as Potential Anti-HIV Agents,”J. Org. Chem., 1992, 57, 7325-7328.
DeFrancesco, R. et al., “Approaching a new era for hepatitis C virus therapy: inhibitors fot eh NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase,”Antiviral Research, 2003, 58, 1-16.
Faivre-Buet, V., et al, “Synthesis of 1′-Deoxypsicofuranosyl-deoxynucleosides as Potential Anti-HIV Agents,”Nucleosides&Nucleotides, 1992, 11(7), 1411-1424.
Farkas, J., et al., “Nucleic acid components and their analogues. XCIV. Synthesis of 6-amino-9-(1-deoxy-□-D-psicofuranosyl)purine”Collect. Czech. Chem. Commun. 1967, 32, 2663-2667.
Farkas, J., “Nucleic acids components and their analogues. LXXIX. Synthesis of methyl 1-deoxy-D-psicofuranosides substituted at C(1) with haolo atoms or a mercapto group,”,Collect. Czech. Chem. Commun. 1966, 31, 1535-1543.
Federov, I.I., et al, “3′-C-branched 2′-deoxy-5-methyluridines: Synthesis, enzyme inhibition, and antiviral properties,”,J. Med. Chem., 1992, 35, 4567-4575.
Franchetti, P., et al, “2′-C-methyl analogues of selective adenosine receptor agonists: Synthesis and binding studies,”J. Med. Chem., 1998, 41, 1708-1715.
Grouiller, A., et al., “Novel p-tolyenesulfonylation and thionocarbonylation of unprotected thymine nucleosides,”Synlett, 1993, 221-222.
Haraguchi, K., et al, “Preparation and reactions of 2′- and 3′- vinyl bromides of uracil-nucleosides: versatile synthons for anti-HIV agents,”Tetrahedron Letters, 1991, 32(28), 3391-3394.
Haraguchi, K., et al, Stereoselective synthesis of 1′-C-branched uracil nucleosides from uridine,Nucleosides&Nucleotides, 1995, 14, 417-420.
Harry-O'Kuru, et al., “A short, flexible route toward 2′-C-branched ribonucleosides”,J. Org. Chem. 1997, 62, 1754-1759.
Harry-O'Kuru, R.E., et al., “2′-C-Alkylribonucleosides: Design, Synthesis, and Conformation,”Nucleosides&Nucleotides, 1997, 16(7-9), 1457-1460.
Hattori, H., et al., “Nucleosides and Nucleotides. 175. Structural requirements of the suga moiety for the antitumor activities of new nucleoside antimetabolites, 1-(3-C-ethynyl-β-D-ribo-p

Affiliated with

Also associated with

Rating

3′-or 2′-hydroxymethyl substituted nucleoside... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 3′-or 2′-hydroxymethyl substituted nucleoside..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3′-or 2′-hydroxymethyl substituted nucleoside... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3657430